• FirefoxInstall the new Firefox »
  •  Dow Down1.14% Nasdaq Down0.79%

    More On GLPGF



    News & Info


    Analyst Coverage

    • Analyst Opinion
    • Analyst Estimates


    • Major Holders
    • Insider Transactions
    • Insider Roster


    • Income Statement
    • Balance Sheet
    • Cash Flow

    Galapagos NV (GLPGF)

    -Other OTC
    19.10 0.00(0.00%) 12:03PM EST
    Add to Portfolio
    ProfileGet Profile for:
    Galapagos NV
    Industriepark Mechelen Noord
    Generaal De Wittelaan L11 A3
    Mechelen, 2800
    Belgium - Map
    Phone: 32 1 534 29 00
    Fax: 32 1 534 29 01
    Website: http://www.glpg.com

    Index Membership:N/A
    Full Time Employees:810

    Business Summary 

    Galapagos NV, a biotech company, discovers and develops small moleculesfor the treatment of cancer, immuno-inflammatory, osteoarthritis, rheumatoid arthritis, and cystic fibrosis diseases. The company’s products under development include GLPG0634, an orally-available, selective inhibitor of Janus kinase 1 that is in Phase IIB clinical trials for the treatment of rheumatoid arthritis (RA) and potentially other inflammatory diseases; and GLPG0778/555, an investigational compound, which is in Phase II studies for the treatment of lupus, ulcerative colitis, and psoriasis. It is also developing GSK2586184, which is in Phase II clinical trials for the treatment of immuno-inflammatory diseases; GLPG0974, an orally available small molecule that is in Phase IB clinical trials to treat neutrophil-driven inflammatory conditions, such as inflammatory bowel disease; and GLPG1205, a drug candidate that completed Phase I clinical trial for the treatment of inflammatory bowel disease. The company has strategic alliances with GlaxoSmithKline, Janssen Pharmaceutica NV, Servier, and AbbVie; and research collaboration agreement with Calchan Holdings Limited. Galapagos NV was founded in 1999 and is headquartered in Mechelen, Belgium.

    Key Statistics

    Company Websites 
    Home Page
    Search Yahoo! for:
    More on Galapagos NV

    Key Executives 
    Mr. Onno van de Stolpe ,
    Co-Founder, Chief Exec. Officer, Managing Director, Exec. Director and Chairman of Exec. Committee
    Mr. Bart Filius , 44
    Chief Financial Officer
    Dr. Piet Wigerinck ,
    Chief Scientific Officer and Member of Exec. Committee
    Ms. Elizabeth Goodwin ,
    Head of Corp. Communications & Investor Relations
    Dr. Andre Hoekema Ph.D.,
    Sr. VP of Corp. Devel. and Member of Exec. Committee
    Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in USD.